Cytori Cell Research Institute, Inc. (JP:3750)
:3750
Top Page
Cytori Cell Research Institute, Inc.
(3750)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥869.00
▲(3.45% Upside)
Action:ReiteratedDate:10/01/25
The score is heavily dragged down by the company's critical financial state, which is the most significant factor. A collapse in revenue and profitability, a dangerously high debt load, and significant cash burn signal severe operational and financial distress. The unattractive valuation, reflected by a negative P/E ratio due to unprofitability, further weakens the stock's profile. Technical indicators are mixed and do not provide a strong counter-argument to the overwhelming fundamental weaknesses.
Positive Factors
Proprietary Technology
Cytori's proprietary technology in regenerative medicine provides a competitive edge, allowing it to offer unique cell-based therapies that can drive long-term growth and market differentiation.
Negative Factors
Revenue Decline
A significant decline in revenue growth indicates challenges in maintaining sales momentum, which could impact long-term financial stability and necessitates a strategic overhaul to reverse the trend.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Technology
Cytori's proprietary technology in regenerative medicine provides a competitive edge, allowing it to offer unique cell-based therapies that can drive long-term growth and market differentiation.
Read all positive factors
Cytori Cell Research Institute, Inc. (3750) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.38B
Dividend YieldN/A
Average Volume (3M)5.90K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth-93.79%
EPS Growth-1332.86%
CountryJP
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-20.81
Shares Outstanding8,929,419
10 Day Avg. Volume2,510
30 Day Avg. Volume5,903
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.36
Price to Sales (P/S)58.59
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cytori Cell Research Institute, Inc. Business Overview & Revenue Model
Company Description
Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell ther...
How the Company Makes Money
Cytori generates revenue through a combination of product sales, research grants, and strategic partnerships. Its core revenue streams include the commercialization of its cell therapy products and related medical devices, which are marketed to ho...
Cytori Cell Research Institute, Inc. Financial Statement Overview
Summary
Income Statement
2
Very Negative
Balance Sheet
5
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.83M | 122.20M | 1.56B | 2.14B | 1.34B | 1.39B |
| Gross Profit | -32.86M | -55.56M | 1.08B | 988.61M | 622.73M | 536.43M |
| EBITDA | -663.11M | -757.31M | -518.43M | -462.87M | -141.28M | -423.82M |
| Net Income | -1.83B | -2.14B | 138.16M | -1.06B | -77.63M | -831.86M |
Balance Sheet | ||||||
| Total Assets | 735.36M | 3.54B | 5.82B | 14.09B | 16.01B | 14.92B |
| Cash, Cash Equivalents and Short-Term Investments | 369.76M | 255.98M | 1.04B | 1.12B | 851.56M | 1.07B |
| Total Debt | 0.00 | 2.65B | 2.47B | 8.51B | 9.27B | 8.53B |
| Total Liabilities | 246.54M | 2.91B | 3.02B | 11.43B | 12.29B | 11.38B |
| Stockholders Equity | 488.81M | 630.54M | 2.79B | 2.65B | 3.71B | 3.55B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -995.12M | -1.17B | -198.04M | -367.83M | -98.86M |
| Operating Cash Flow | 0.00 | -987.04M | -1.15B | -39.52M | -187.78M | -82.90M |
| Investing Cash Flow | 0.00 | 22.90M | 8.69B | -283.06M | -216.19M | 381.79M |
| Financing Cash Flow | 0.00 | 171.65M | -7.17B | 294.23M | 35.80M | -224.44M |
Cytori Cell Research Institute, Inc. Technical Analysis
Negative
840.00
Price Trends
869.28
Negative
852.84
Negative
863.46
Negative
Market Momentum
-11.25
Positive
36.57
Neutral
26.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3750, the sentiment is Negative. The current price of 840 is below the 20-day moving average (MA) of 868.15, below the 50-day MA of 869.28, and below the 200-day MA of 863.46, indicating a bearish trend. The MACD of -11.25 indicates Positive momentum. The RSI at 36.57 is Neutral, neither overbought nor oversold. The STOCH value of 26.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3750.
Cytori Cell Research Institute, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥7.84B | 59.41 | ― | 1.24% | -14.78% | -95.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.41B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥50.09B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.20B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥18.99B | -11.30 | ― | ― | ― | 11.34% | |
43 Neutral | ¥7.38B | -10.09 | ― | ― | -93.79% | -1332.86% |
* Healthcare Sector Average
JP:3750
Cytori Cell Research Institute, Inc.
830.00
160.00
23.88%
JP:4593
Healios KK
344.00
122.00
54.95%
JP:4599
StemRIM Inc.
312.00
41.00
15.13%
JP:4880
CellSource Co., Ltd.
396.00
-212.89
-34.96%
JP:7774
Japan Tissue Engineering Co., Ltd.
604.00
199.00
49.14%
JP:7776
CellSeed Inc.
285.00
-182.00
-38.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.